Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 38


Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Namiki M, Ueno S, Kitagawa Y.

Transl Androl Urol. 2012 Sep;1(3):160-72. doi: 10.3978/j.issn.2223-4683.2012.07.03. Review.


Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Kunath F, Borgmann H, Blümle A, Keck B, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ.

BMJ Open. 2015 Nov 13;5(11):e008217. doi: 10.1136/bmjopen-2015-008217.


Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.

Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.


Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.

BMC Cancer. 2015 May 20;15:420. doi: 10.1186/s12885-015-1429-0.


Metabolic effects of androgen deprivation therapy.

Choi SM, Kam SC.

Korean J Urol. 2015 Jan;56(1):12-8. doi: 10.4111/kju.2015.56.1.12. Epub 2015 Jan 6. Review.


Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, Penson DF.

J Urol. 2015 Apr;193(4):1226-31. doi: 10.1016/j.juro.2014.11.006. Epub 2014 Nov 11.


Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study.

Lebret T, Davin JL, Hennequin C, Latorzeff I, Mignard JP, Moreau JL, Rossi D, Ruffion A, Zerbib M, Culine S.

Ther Adv Urol. 2014 Dec;6(6):205-14. doi: 10.1177/1756287214542418.


Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications.

Hu CS, Wu QH, Hu DY.

J Thorac Dis. 2014 Sep;6(9):1319-28. doi: 10.3978/j.issn.2072-1439.2014.07.15. Review.


Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

Phillips I, Shah SI, Duong T, Abel P, Langley RE.

Oncol Hematol Rev. 2014 Spring;10(1):42-47.


Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.

Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK, Lam KS, Tse HF, Yau T, Siu CW.

J Oncol. 2014;2014:529468. doi: 10.1155/2014/529468. Epub 2014 Apr 7.


Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.

Yin L, Hu Q, Hartmann RW.

Int J Mol Sci. 2013 Jul 4;14(7):13958-78. doi: 10.3390/ijms140713958. Review.


Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.

Kunath F, Keck B, Rücker G, Motschall E, Wullich B, Antes G, Meerpohl JJ.

BMC Cancer. 2013 Mar 19;13:131. doi: 10.1186/1471-2407-13-131. Review.


The opportunity cost of androgen suppression in locally advanced prostate cancer.

Gray PJ, Efstathiou JA, Shipley WU.

Asian J Androl. 2013 May;15(3):356-7. doi: 10.1038/aja.2012.166. Epub 2013 Feb 25. No abstract available.


Androgen deprivation therapy toxicity and management for men receiving radiation therapy.

Johnson ME, Buyyounouski MK.

Prostate Cancer. 2012;2012:580306. doi: 10.1155/2012/580306. Epub 2012 Dec 30.


Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ.

Br J Cancer. 2013 Jan 15;108(1):9-13. doi: 10.1038/bjc.2012.523. Epub 2012 Nov 29. Review.


Radical radiotherapy for high-risk prostate cancer in older men.

Payne HA, Hughes S.

Oncologist. 2012;17 Suppl 1:9-15.


Radiation treatment for patients with intermediate-risk prostate cancer.

Greene DE, Mayadev JS, Valicenti RK.

Ther Adv Urol. 2012 Jun;4(3):113-24. doi: 10.1177/1756287212442977.


The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.

Smith MJ, Akhtar NH, Tagawa ST.

Prostate Cancer. 2012;2012:280278. doi: 10.1155/2012/280278. Epub 2012 Apr 24.


Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.

Saylor PJ, Karoly ED, Smith MR.

Clin Cancer Res. 2012 Jul 1;18(13):3677-85. doi: 10.1158/1078-0432.CCR-11-3209. Epub 2012 May 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk